Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials

被引:0
作者
Gottlieb, A. B. [1 ]
Thaci, D. [2 ]
Leonardi, C. [3 ,4 ]
Poulin, Y. [5 ]
Kavanagh, S. [6 ]
Boehnlein, M. [7 ]
Reich, K. [8 ,9 ]
机构
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Lubeck, Lubeck, Germany
[3] Cent Dermatol, St Louis, MO USA
[4] St Louis Univ, Sch Med, St Louis, MO USA
[5] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[6] UCB Pharma, Raleigh, NC USA
[7] UCB Pharma, Monheim, Germany
[8] SCIderm Res Inst, Hamburg, Germany
[9] Dermatologikum Berlin, Berlin, Germany
关键词
Certolizumab Pegol; Nail disease; Psoriasis;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P116
引用
收藏
页码:54 / 54
页数:1
相关论文
共 3 条
[1]   Validity of the rheumatoid arthritis MRI score applied to the forefeet using the OMERACT filter: a systematic literature review [J].
Dakkak, Yousra J. ;
van der Heijde, Desiree M. ;
Reijnierse, Monique ;
van der Helm-van Mil, Annette H. M. .
RMD OPEN, 2018, 4 (02)
[2]   Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) [J].
Gottlieb, Alice B. ;
Blauvelt, Andrew ;
Thaci, Diamant ;
Leonardi, Craig L. ;
Poulin, Yves ;
Drew, Janice ;
Peterson, Luke ;
Arendt, Catherine ;
Burge, Daniel ;
Reich, Kristian .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) :302-+
[3]  
Lebwohl M, 2018, J AM ACAD DERMATOL, V79